Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment

MLA

Bing Han, et al. “Stanozolol Improves the Progression-Free Survival of Patients with High-Risk Myelodysplastic Syndrome after Decitabine Treatment.” International Journal of Hematology, vol. 113, no. 6, Oct. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a9fb705606462d73d0d57049a4280704&authtype=sso&custid=ns315887.

APA

Bing Han, Yumei Liu, Haiyue Niu, Luoming Hua, Zonghong Shao, Jingbo Wang, Fang Ye, Chen Yang, Hua Xue, Weiwei Qi, Huaquan Wang, & Wanling Sun. (2020). Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment. International Journal of Hematology, 113(6).

Chicago

Bing Han, Yumei Liu, Haiyue Niu, Luoming Hua, Zonghong Shao, Jingbo Wang, Fang Ye, et al. 2020. “Stanozolol Improves the Progression-Free Survival of Patients with High-Risk Myelodysplastic Syndrome after Decitabine Treatment.” International Journal of Hematology 113 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a9fb705606462d73d0d57049a4280704&authtype=sso&custid=ns315887.